“The goal of the UCSF Digital Health Awards is to ultimately help patients access amazing innovations by recognizing and awarding the great companies with the best in-market digital products and services." Health Hub describes.
FAYETTEVILLE, Ark. (PRWEB) October 20, 2022
The University of California San Francisco (UCSF) Health Hub has selected CardioWise, Inc. as a Digital Health Awards Finalist in the Rising Star Clinical Diagnostics Tool or Platform category. The UCSF Health Hub Digital Health Awards recognizes the achievements of innovative health tech companies that are dramatically improving healthcare through the use of technology in the digital health industry. Companies from all across the world will be evaluated by our panel of esteemed judges from the digital health world. The Grand Finale will crown two winners from each category. Specifically, the Rising Star digital diagnostic technology is for point-of-care monitoring that can significantly improve decision-making in the clinical setting. The awards are intended to showcase new technologies that are dramatically improving healthcare through innovative means, to benefit society and to reduce the onerous cost burden. Over 1250 companies participated, representing eleven categories, with over 100 judges.
As described by the Health Hub: “The goal of the UCSF Digital Health Awards is to ultimately help patients access amazing innovations by recognizing and awarding the great companies with the best in-market digital products and services. The live event, held in San Francisco on November 14, 2022, will be live-streamed and is the first of its kind patient and clinician oriented awards event.”
“We are proud to have been chosen as a Finalist in the Rising Star Clinical Diagnostic category of the 2022 UCSF Digital Health Awards,” said Jack Coats, CEO of CardioWise. “UCSF is recognized as an expert in digital health and has a superlative reputation, currently 3rd in the US News national hospital rankings. For a startup company like CardioWise to have been chosen from over 1250 applications by a team of 100 prestigious judges, all organized by UCSF, is truly an honor and a tribute to our fine development team led by Geoffrey Dalbow, CardioWise CTO.”
CardioWise™ is commercializing patented, non-invasive Cardiac CT analysis software that produces a quantified 4D image model of the human heart, called Stretch Quantifier for Endocardial Engraved Zones™ (SQuEEZ™). CardioWise heart analysis software combined with cardiac CT is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise™ is a VIC Technology Venture Development™ portfolio company.